A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
MedicinaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The oncologist
- Publicado em
- 22 jul 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Laurent Zelek, Philippe Debourdeau, Hugues Bourgeois, Jean Philippe Wagner, Fabien Brocard, Claudia Lefeuvre-Plesse, Bruno Chauffert, Marianne LeHeurteur, Jean Baptiste Bachet, Hélène Simon et al.
Descritores MeSH
- Antineoplastic Agents
- Antiemetics
- Antibiotics, Antineoplastic
- Double-Blind Method
- Humans
- Isoquinolines
- Nausea
- Prospective Studies
- Quinuclidines
- Aprepitant
Estudos relacionados
- Single versus two doses of palonosetron for prevention of chemotherapy-induced nausea and vomiting in children: a double-blind placebo controlled randomized study
- Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis
- Um estudo farmacocinético e farmacodinâmico de fase 2 do NEPA oral para náuseas e vómitos induzidos pela quimioterapia em pacientes pediátricos com câncer
- Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy